

**EVALUATION OF ULTRASONIC TRANSIENT
ELASTOGRAPHY (FIBROSCAN) IN EGYPTIAN
CHRONIC HCV PATIENTS**

Thesis Submitted for fulfillment of MD degree in Tropical Medicine

By

AISHA MAHMOUD ABDEL-AZIZ

M.B.B.Ch, MSc

SUPERVISORS

DR. SAMEH LABIB

Professor of Tropical Medicine

Faculty of Medicine - Cairo University

DR. GAMAL ESMAT

Professor of Tropical Medicine

Faculty of Medicine - Cairo University

DR. MOSTAFA KAMAL

Professor of public health

Faculty of Medicine - Ain shams University

DR. HANI KHATTAB

Professor of pathology

Faculty of Medicine – Cairo University

Faculty of Medicine

Cairo University

2010

ACKNOWLEDGEMENT

*“He, and will always be, Allah who always blessed my work
And who sent me those who were of help “*

I am greatly honored to express my deep gratitude and faithfulness to Dr. Sameh Labib, Professor of Tropical Medicine, Cairo University. He gave me his valuable advices and support that cannot be expressed in words.

My deep thanks and appreciation to Dr. Gamal Esmat, Professor of Tropical Medicine, Cairo University, for his strict supervision and revision of this work, he gave me much of his time, experience and support, His fatherhood attitude and encouragement were so supportive for the completion of this work.

I would like to thank Dr. Mostafa Kamal, Professor of Community medicine, Ain Shams University, for his kindness, generous help, goodness, sincere encouragement and patience with me.

I would like to thank Dr. Hany Khattab, Professor of Pathology, Cairo University for his sincere guidance and his help throughout the work. To him therefore, I express my deep sense of gratitude.

I would like to thank ,DR,Khaled zalata , Professor of Pathology, Mansora University for his help and support throughout the work.

I am extremely grateful to Dr.Maissa Elraziky, Professor of Tropical Medicine, Cairo University, she never let me down and she was always standing by me when I needed her help and advice.

ACKNOWLEDGEMENT

I would like to thank Dr Wafaa Elakel assistant Professor of Tropical Medicine, Cairo University, for her help, advice and support throughout the work.

I would like to thank all staff members of the National Hepatology and Tropical Medicine Research Institute (NHTMRI) and all team members of (fibrosis markers project) both Egyptian and french members for their help and support throughout the work.

I would like to thank all my staff members of the Tropical Medicine Department, Cairo University, especially Dr. Mahasen Abdel-Rahman the head of the department for her continuous guidance, encouragement and support for me and my colleagues.

My deep thanks to all my colleagues in Kasr ElAini and in (NHTMRI) for their help and support and to all patients included in this work and every one made any effort for this work to be a reality.

A special dedication to my family for their never ending care. They were always supporting me and encouraging me to continue and finish this work.

Aisha El-Sharkawy

ABSTRACT

Diagnosis of the stage of liver fibrosis is essential for making a prognosis and deciding an antiviral therapy. Liver biopsy is the gold standard for fibrosis staging, but due to its limitations, alternative tests for liver fibrosis evaluation have been developed. Among them, serum markers and transient elastography have been compared against histology.

Aim of work: Evaluate the efficacy of transient elastography in the diagnosis of hepatic fibrosis among Egyptian chronic HCV patients.

Patients and methods: Our study included 197 chronic HCV patients and for them routine investigations, ultrasound guided liver biopsy and liver stiffness measurement using fibroscan were done. All biopsy specimens were analyzed by two experienced pathologists blinded to the results of each other and were classified according to the specimen length into ideal biopsy, subideal biopsy and not accepted.

Results: 1- inter-observer variability between pathologists is less evident in fibrosis staging and is not related to the liver biopsy specimen length.

2- Fibroscan is a sensitive tool in detection of significant fibrosis $F \geq 2$ as assessed by the METAVIR score at a cut off level of 6.35 kpa and in detection of cirrhosis $F \geq 4$ at a cut off level of 10.75 kpa.

3- Schistosomal infection decrease the sensitivity of the new fibroscan score cut off level to detect significant fibrosis (F2-F3) as assessed by the METAVIR scoring system.

Key words: liver fibrosis, transient elastography (fibroscan), liver biopsy

Table of contents

Introduction and aim of the work.....	1
Review of literature.....	
- <u>Chapter I</u> : Liver fibrosis.....	4
- <u>Chapter II</u> : Invasive assessment of liver fibrosis (liver biopsy).....	31
- <u>Chapter III</u> : Non invasive assessment of liver fibrosis	46
Patients and Methods.....	64
Results.....	70
Discussion.....	94
Summary and Conclusions.....	102
Recommendations.....	106
References.....	107
المُلخَص العربي	

LIST OF TABLES

Table I	Therapeutic Strategies for Hepatic Fibrosis.	24
Table II	The Grading and Staging System of Ishak et al, 1995.	44
Table III	Serum indices for noninvasive evaluation of fibrosis.	48
Table IV	TE cut-off values for the diagnosis of METAVIR fibrosis score.	56
Table1(a)	Demographic features of the studied patients	70
Table1(b)	Sex distribution of the studied patients.	70
Table 2	The biochemical profile of the studied patients.	71
Table 3	Positive schistosomal serology in the studied patients.	72
Table 4	Liver Ultrasound of the studied patients.	72
Table 5	Fibrosis stages in liver biopsy according to Metavir scoring system for pathologist 1.	72
Table 6	Activity grade in liver biopsy according to Metavir scoring system for pathologist 1.	73
Table 7	Fibrosis stages in liver biopsy according to Metavir scoring system for pathologist 2	73

LIST OF TABLES

Table 8	Activity in liver biopsy according to Metavir scoring for pathologist 2	74
Table 9	classification of liver biopsies according to the specimen length and number of portal tracts	74
Table 10	Comparing fibrosis stages according to Metavir scoring system in all biopsy specimens for both pathologists.	75
Table 11	Comparing Fibrosis stages in the ideal biopsies according to METAVIR scoring system for both pathologists.	75
Table 12	Comparing Fibrosis stages according to METAVIR scoring system in the subideal biopsies for both pathologists.	76
Table 13	The agreement and disagreement between the two pathologists in relation to the specimen length.	76
Table 14	Comparing activity grades according to Metavir scoring system in all biopsy specimens for both pathologists.	76
Table 15	Comparing F1 for both pathologists	77
Table 16	Comparing F2 for both pathologists	78
Table 17	Comparing F3 for both pathologists.	79
Table 18	sComparing F4 for both pathologists:	80

Table 19	ultrasound results in relation to presence of cirrhosis by histopathology	81
Table 20	Results of the fibroscan in the studied population .	82
Table 21	Activity grade according to METAVIR scoring system in relation to the fibroscan score.	82
Table 22	fibrosis stage according to METAVIR scoring in relation to fibroscan score	82
Table 23	Comparing these fibrosis groups with fibroscan score.	84
Table 24	Validation of the new fibroscan cut off level and its application on the fibrosis groups of studied patients.	87
Table 25	Validation of Castera cut off level and its application on the fibrosis groups of studied patients	88
Table 26	comparing sensitivity and positive predictive value of both our new fibroscan cut off and castera cut off level when applied on our Egyptian population	89
Table 27	Fibrosis stages in patients with positive schistosomal serology .	91
Table 28	Validation of the new cut off level when applied on patients with positive schistosomal serology.	91

Table 29	Fibrosis stage according to METAVIR scoring for the ideal biopsies with agreement between the pathologists in relation to fibroscan score	93
Table 30	Application of this cut off level on the groups of fibrosis as assessed by the METAVIR scoring system	93

LIST OF FIGURES

Figure I	Matrix and cellular alterations in hepatic fibrosis.	6
Figure II	Morphology of hepatic stellate cells in normal liver.	8
Figure III	Pathways of stellate cell activation and resolution.	18
Figure IV	Transient elastography device.	50
Figure V	Technique and probe position.	51
Figure VI	Proposed algorithm combining transient elastography and serum indice (fibrotest) for the first-line noninvasive assessment of hepatic fibrosis in patients with chronic viral hepatitis.	60
Figure VII	SAFE biopsy algorithm for significant fibrosis \geqF2 by Metavir.	61
FigureVIII	The SAFE-biopsy algorithm for cirrhosis (F4 by METAVIR).	62
Figure IX	Data appearing on the screen of the device during examination	67
Figure 1	Comparing F1 for both pathologists	77

LIST OF FIGURES

Figure 2	Comparing F2 for both pathologists	78
Figure 3	Comparing F3 for both pathologists	79
Figure 4	Comparing F4 for both pathologists:	80
Figure 5	ultrasound results in relation to presence of cirrhosis by histopathology	81
Figure 6	fibrosis stage according to METAVIR scoring in relation to fibroscan score	83
Figure 7	Comparing these fibrosis groups with fibroscan score	84
Figure 8	ROC curve to detect new fibroscan score cutoff level between F0-F1 and F2-F3	85
Figure 9	ROC curve to detect new fibroscan score cutoff level between F2-F3 and F4	86
Figure 10	Validation of the new fibroscan cut off level and its application on the fibrosis groups of studied patients	87
Figure 11	Validation of Castera cut off level and its application on the fibrosis groups of studied patients	88

LIST OF FIGURES

Figure 12	comparing the sensitivity of both our new fibroscan cut off and castera cut off level when applied on our Egyptian population	89
Figure 13	comparing the positive predictive value of both our new fibroscan cut off and castera cut off level when applied on our Egyptian population	90
Figure 14	validation of our new fibroscan cut off level on patients with positive schistosomal serology	92

LIST OF ABBREVIATIONS

- **ACE:** angiotensinogen converting enzyme
- **APASL:** Asian pacific assoaiation for study of liver disease
- **APRI:** AST-to-Platelet ratio Index
- **AT:** angiotensin
- **AUROC:** Area under ROC curve
- **BMI :** body mass index
- **CCl4 :** carbon tetrachloride
- **CCN:** Cysteine rich neuroblastoma overexpressed
- **CTGF:** connective tissue growth factor
- **EBP β :** enhancer binding protein – β
- **ECM :** extracellular matrix proteins
- **ELF :** Enhanced Liver Fibrosis Test
- **EMT:** epithelial–mesenchymal transition
- **ET-1:** Endothelin-1
- **FGF:** fibroblast growth factor
- **FXR:** farnesyl X receptor
- **HGF:** Hepatocyte growth factor
- **HMG CoA:** 3-hydroxy-3-methyl-glutaryl coenzyme A
- **HSC:** hepatic stellate cell
- **HVPG :** hepatic-vein portal gradient
- **ICAM :** intacellualr adhesion molecule
- **ICC :** intraclass correlation coefficients
- **IL-3:** Interleukin 3
- **IQR :** The interquartile range
- **LPS:** lipopolysaccharide
- **M-CSF:** macrophage colony-stimulating factor
- **MCP:** monocyte chemotactic peptide
- **MMPs :**matrix metalloproteinase
- **NCAM:** neural cell adhesion molecule

- **NF Kappa B:** nuclear factor-Kappa B
- **NGF:** nerve growth factor
- **NO:** nitric oxide
- **NOTES:** natural orifice transluminal endoscopic surgery
- **NPV:** Negative predictive value
- **PDGF :** platelet derived growth factors
- **PDTC:** pyrrolidine dithiocarbamate
- **PPAR:** peroxisome proliferators activated receptor
- **PPV:** Positive predictive value
- **ROC curve:** Receiver operator characteristic curve
- **ROS:** reactive oxidative stress
- **SAFE biopsy :** Sequential algorithms for fibrosis evaluation
- **Smad 7:** mothers against DPP homolog 7
- **SOD :** superoxide dismutase-system
- **SOS :** sinusoidal obstruction syndrome
- **(TE):** transient elastography
- **TGF-b:** Transforming growth factor-b
- **TIMPs:** the tissue inhibitors of metalloproteinases
- **TLRs:** toll-like receptors
- **TNF-a:** Tumor necrosis factor a
- **TRAIL:** TNF-related apoptosis-inducing ligand
- **VCAM:** vascular cell adhesion molecule
- **VEGF:** Vascular endothelial growth factor

INTRODUCTION

Chronic hepatitis C virus (HCV) infection is responsible for liver fibrosis and may lead to potential long-term complications such as liver cirrhosis and hepatocellular carcinoma. (*Franck et al, 2000*).

In Egypt about 13.3 % of population are chronically infected with HCV and are at risk of liver complications .Individuals living in rural areas had significantly more anti-HCV seropositivity (36.1%) than those living in urban areas (24.7%) (*Mohamed, 2004*)

This high prevalence has been attributed to transmission through insufficiently sterilised needles during mass anti-bilharzial treatment campaigns in the 1960s and 1970s. Epidemiological studies have shown that genotype 4 (HCV-G4) was the most frequent (91%) genotype isolated in Egypt (*Ray et al, 2000*).

Diagnosis of the stage of liver fibrosis is essential for making a prognosis and deciding an antiviral therapy. Liver biopsy is the gold standard for fibrosis staging, although it is limited by its invasive nature, poor acceptance, availability, cost, intra- and interobserver variability, and sampling errors (*Cadranel et al, 2000*).

To avoid biopsy, alternative tests for liver fibrosis evaluation have been developed. Among them, serum markers and elastometry are the two main techniques which have been compared against histology. Serum markers have been the first to appear, and typically combine several indicators, among which $\alpha 2$ macroglobuline, haptoglobin, apolipoprotein A1, bilirubin,